Biotransformations in Drug Metabolism

Drug Metabolism Handbook: Concepts and Applications

Volumn , Issue , 2008, Pages 17-40

  King, Roberta S ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Biotransformations in drug metabolism; Enzymology and modifiers of CYPs; Oxidations and cytochrome P 450

Indexed keywords

EID: 84889817322     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470439265.ch3     Document Type: Chapter

References (24)

1. Bornheim, L.M., Lasker, J.M., Raucy, J.L. (1992). Human hepatic microsomal metabolism of delta 1-tetrahydrocannabinol. Drug Metab. Dispos., 20 (2), 241-246.
2. Emoto, C., Murase, S., Iwasaki, K. (2006). Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage. Xenobiotica, 36 (8), 67-683.
3. Evans, W.E., Relling, M.V. (1999). Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286, 487-491.
4. Fuccella, L.M., Tamassia, V., Valzelli, G. (1973). Metabolism and kinetics of the hypoglycemic agent glipizide in man: comparison with glibenclamide. J. Clin. Pharmacol., 13, 68-75.
5. Guengerich, F.P. (1987). Oxidative cleavage of carboxylic esters by cytochrome P-450. J. Biol. Chem., 262 (18), 8459-8462.
6. Guengerich, F.P. (2001). Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol., 14 (6), 611-650.
7. Guengerich, F.P., McDonald, T.L. (1984). Chemical mechanisms of catalysis by cytochromes P-450: a unified view. Acc. Chem. Res., 17, 9-16.
8. Hamman, M.A., Thompson, G.A., Hall, S.D. (1997). Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem. Pharmacol., 54 (1), 33-41.
9. Hines, R.N. (2007). Ontogeny of human hepatic cytochromes P450. J. Biochem. Mol. Toxicol., 21 (4), 169-175.
10. Ingelman-Sundberg, M., Sim, S.C., Gomez, A., R odriguez-Antona, C. (2007). I nfluence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther., 116, 496-526.
11. Lemberger, L. (1973). Tetrahydrocannabinol metabolism in man. D rug Metab. Dispos., 1 (1), 461-468.
12. Lewis, D.F.V. (2003). Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch. Biochem. Biophys., 409, 32-44.
13. Monahan, B.P., Ferguson, C.L., Killeavy, E.S., Lloyd, B.K., Troy, J., Cantilena, L.R., Jr (1990). Torsades de pointes occurring in association with terfenadine use. JAMA, 264 (21), 2788-2790.
14. Paulson, S.K., Hribar, J.D., Liu, N.W., Hajdu, E., Bible, R.H., Jr, Piergies, A., Karim, A. (2000). Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers. Drug Metab. Dispos., 28 (3), 308-314.
15. Peng, H.-W., Raner, G.M., Vaz, A.D.N., C oon, M.J. (1995). O xidative cleavage of esters and amides to carbonyl products by cytochrome P450. Arch. Biochem. Biophys., 318 (2), 333-339.
16. Rudy, A.C., Knight, P.M., Brater, D.C., Hall, S.D. (1991). Stereoselective metabolism of ibuprofen in humans: administration of R -, S-and racemic ibuprofen. J. Pharmacol. Exp. Ther., 259 (3), 1133-1139.
17. Rudy, A.C., Knight, P.M., Brater, D.C., Hall, S.D. (1991). Stereoselective metabolism of ibuprofen in humans: administration of R -, S-and racemic ibuprofen. J. Pharmacol. Exp. Ther., 259 (3), 1133-1139.
18. Sheridan, R.P., Korzekwa, K.R., Torres, R.A., Walker, M.J. (2007). Empirical regioselectivity models for human cytochromes P450 3A4, 2D6, and 2C9. J. Med. Chem., 50 (14), 3173-3184.
19. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., Guengerich, F.P. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270 (1), 414-423.
20. Tang, C., Shou, M., Mei, Q., Rushmore, T.H., Rodrigues, A.D. (2000). Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J. Pharmacol. Exp. Ther., 293 (2), 453-459.
21. Terfloth, L., Bienfait, B., Gasteiger, J. (2007). Ligand-based models for the isoform specificity of cytochrome P450 3A4, 2D6, and 2C9 substrates. J. Chem. Inf. Model., 47, 1688-1701.
22. Totah, R.A., Rettie, A.E. (2005). Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin. Pharmacol. Ther., 77 (5), 341-352.
23. Williams, R.T. (1947). Detoxication Mechanisms: The Metabolism of Drugs and Allied Organic Compounds. Chapman and Hall, London.
24. Zanger, U.M., Raimundo, S., Eichelbaum, M. (2004). Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol., 369 (1), 23-37.